Opdivo® (nivolumab) – Expanded indications
February 15, 2023 - The FDA approved Bristol Myers Squibb Opdivo (nivolumab), as a single agent or in combination with Yervoy® (ipilimumab), for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.
Download PDF
